Search Result

Results for "

efficacy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (25) ADC Cytotoxin (2) Adenylate Cyclase (1) Adrenergic Receptor (10) AIM2 (1) Akt (8) Aldose Reductase (1) Aminoacyl-tRNA Synthetase (1) AMPK (3) Amylin Receptor (1) Amyloid-β (6) Anaplastic lymphoma kinase (ALK) (2) Androgen Receptor (4) Angiotensin Receptor (2) Angiotensin-converting Enzyme (ACE) (2) Antibiotic (28) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (86) Aurora Kinase (1) Autophagy (11) Bacterial (64) Bcl-2 Family (4) Bcr-Abl (4) Beta-lactamase (1) Biochemical Assay Reagents (6) Btk (4) c-Fms (2) c-Kit (3) c-Met/HGFR (9) c-Myc (1) Calcium Channel (11) Cannabinoid Receptor (2) Carbonic Anhydrase (2) Casein Kinase (2) Caspase (5) Cathepsin (1) CD3 (1) CD73 (1) CDK (13) CFTR (1) CGRP Receptor (1) Chloride Channel (2) Cholinesterase (ChE) (7) ClpP (1) Complement System (2) COX (3) CXCR (2) Cytochrome P450 (3) Dengue virus (4) Deubiquitinase (2) Dihydroorotate Dehydrogenase (2) Dipeptidyl Peptidase (2) Discoidin Domain Receptor (2) DNA-PK (1) DNA/RNA Synthesis (18) Dopamine Receptor (9) Drug Metabolite (4) Drug-Linker Conjugates for ADC (4) DYRK (6) E1/E2/E3 Enzyme (2) EGFR (16) Endogenous Metabolite (6) Epigenetic Reader Domain (7) Epoxide Hydrolase (3) ERK (8) Estrogen Receptor/ERR (8) FAAH (2) FAK (1) FAP (1) Fatty Acid Synthase (FASN) (2) Ferroptosis (4) FGFR (5) Filovirus (1) FLAP (1) Flavivirus (5) FLT3 (6) Fluorescent Dye (2) Fungal (8) FXR (2) GABA Receptor (12) GCGR (2) GLP Receptor (3) Glucocorticoid Receptor (1) Glucokinase (2) Glucosidase (5) GLUT (2) Glutaminase (1) GnRH Receptor (2) GSK-3 (2) HBV (2) HCV (1) HDAC (17) Histamine Receptor (9) Histone Acetyltransferase (1) Histone Demethylase (2) Histone Methyltransferase (3) HIV (11) HIV Protease (2) HSP (11) HSV (1) HuR (1) IAP (1) IFNAR (2) iGluR (6) IKK (2) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (4) Integrin (3) Interleukin Related (5) IRAK (1) Isotope-Labeled Compounds (14) Itk (1) JAK (7) JNK (1) Keap1-Nrf2 (4) Kinesin (1) Ligands for E3 Ligase (1) Lipase (1) Liposome (2) Lipoxygenase (2) LPL Receptor (4) MAGL (1) MAP4K (4) MDM-2/p53 (5) MEK (2) Melanocortin Receptor (2) MetAP (1) mGluR (5) Microtubule/Tubulin (13) Mitochondrial Metabolism (6) MMP (3) MNK (1) Molecular Glues (1) Monoamine Oxidase (3) mTOR (8) Myosin (1) N-myristoyltransferase (1) nAChR (5) NADPH Oxidase (1) NAMPT (4) Necroptosis (1) NEKs (2) Neurokinin Receptor (1) NF-κB (12) NO Synthase (5) NOD-like Receptor (NLR) (4) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (2) Orexin Receptor (OX Receptor) (1) P-glycoprotein (8) P2X Receptor (3) P2Y Receptor (3) p38 MAPK (3) PAI-1 (1) PAK (1) Parasite (17) PARP (8) PCSK9 (2) PD-1/PD-L1 (9) PDGFR (3) PERK (2) Phosphatase (1) Phosphodiesterase (PDE) (8) Phospholipase (3) PI3K (14) PI4K (2) Pim (4) PKC (1) Polo-like Kinase (PLK) (4) Potassium Channel (17) PPAR (20) Progesterone Receptor (2) Prolyl Endopeptidase (PREP) (2) Prostaglandin Receptor (8) PROTACs (18) Protease Activated Receptor (PAR) (2) Proteasome (2) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (1) Raf (5) Ras (9) Reactive Oxygen Species (9) Renin (3) RET (2) Reverse Transcriptase (3) ROCK (1) ROR (3) ROS Kinase (1) RSV (2) SARS-CoV (12) Serotonin Transporter (5) SGLT (2) SHP2 (2) Sigma Receptor (2) Sirtuin (1) Sodium Channel (13) Somatostatin Receptor (2) Src (1) STAT (7) Stearoyl-CoA Desaturase (SCD) (2) STING (6) Survivin (2) TAM Receptor (4) Target Protein Ligand-Linker Conjugates (6) TGF-beta/Smad (1) Tim3 (1) TNF Receptor (3) Toll-like Receptor (TLR) (4) Topoisomerase (6) Transthyretin (TTR) (3) Trk Receptor (7) TRP Channel (4) Tryptophan Hydroxylase (1) URAT1 (3) VD/VDR (1) VEGFR (13) Virus Protease (3) Xanthine Oxidase (1) YAP (2) α-synuclein (2) β-catenin (3) γ-secretase (2)
By Research Areas:	Cancer (405) Cardiovascular Disease (48) Endocrinology (17) Infection (149) Inflammation/Immunology (119) Metabolic Disease (60) Neurological Disease (153)
Click Chemistry:	Azide (1) Alkynes (6)
Oligonucleotides:	Nucleosides and their Analogs (2) Aptamers (2) Cationic Lipids (1) Cholesterol (1)

865

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150256

YTP-17	YAP	Cancer
YTP-17 is an orally active YAP-TEAD protein-protein interaction inhibitor with an IC₅₀ of 4 nM. YTP-17 shows anti-tumor efficacy .

HY-146185

CCT373566	Bcl-2 Family	Cancer
CCT373566 is a potent and orally active degrader of transcriptional repressor BCL6, with an IC₅₀ of 2.2 nM. CCT373566 shows strong antiproliferative efficacy in vitro and reduction in tumor growth in vivo .

HY-139303

LUF5771	Others	Endocrinology
LUF5771 is a potent allosteric recombinant luteinizing hormone (recLH) and Org 43553 inhibitor. LUF5771 is able to partially activate the LH receptor with low efficacy .

HY-108493

CS-2100	LPL Receptor	Inflammation/Immunology
CS-2100 (Compound 10b) is a potent, selective, orally active and S1P₃-sparing S1P₁ agonist with an EC₅₀ of 4.0 nM for human S1P₁. CS-2100 shows in vivo immunosuppressive efficacy in rats with an ID₅₀ (infective dose) of 0.407 mg/kg for HvGR .

HY-118704

P-2281	mTOR	Inflammation/Immunology Cancer
P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P-2281 suppresses dextran sulfate sodium (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human colitis .

HY-130115

IACS-8803	STING	Cancer
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .

HY-103404

PNU-96415E	Dopamine Receptor 5-HT Receptor	Neurological Disease
PNU-96415E is a selective D₄/5-HT_2A antagonist. PNU-96415E may have potential antipsychotic efficacy .

HY-164484

IHMT-RAF-128	Raf	Cancer
IHMT-RAF-128, a highly potent pan-RAF inhibitor. IHMT-RAF-128 shows potent antitumor efficacy in xenograft mouse tumor models without causing any apparent toxicities .

HY-155647

Microtubule stabilizing agent-1	Microtubule/Tubulin	Cancer
Microtubule stabilizing agent-1 (compound 3l) is a Paclitaxel derivative that efficiently promotes tubulin polymerization. Microtubule stabilizing agent-1 shows antitumor efficacy .

HY-168262

Antitrypanosomal agent 22	Parasite	Infection
Antitrypanosomal agent 22 (compound 13) is a nitrothienylazine compound with trypanosomaticidal efficacy. Antitrypanosomal agent 22 shows leishmanicidal and trypanocidal with in vitro submicromolar activities, and devoid of toxicity on mammalian cells are uncovered .

HY-Y1903

Phosal 50 PG 3 Publications Verification	Biochemical Assay Reagents	Others
Phosal 50 PG is a cosolvent (standardised phosphatidylcholine concentrate). Phosal 50 PG as a carrier for lipophilic compounds, can improve the absorption, efficacy and therapeutic index of the active ingredient .

HY-156511

ETC-168	MNK	Cancer
ETC-168 is a selective and oral active MNK inhibitor with the IC₅₀ values of 23 and 43 nM against MNK1 and MNK2, respectively. ETC-168 shows antiproliferative efficacy in vivo and in vitro .

HY-155146

Anticancer agent 146	Necroptosis	Cancer
Anticancer agent 146 (compound 1.19) is a necroptosis inducer. Anticancer agent 146 has anti-tumor efficacy in the mouse MDA-MB-231 xenograft model .

HY-P99103

Bebtelovimab LY-3853113; LY-COV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-113555

DORA 42	Orexin Receptor (OX Receptor)	Neurological Disease
DORA 42 is a dual orexin 1 and orexin 2 receptor antagonist with sleep efficacy in rats. DORA 42 is promising for research of insomnia .

HY-155250

Antibacterial agent 154	Bacterial	Infection
Antibacterial agent 154 (compound 7) is a derivative of Fluoroqinolones and is an orally effective antibacterial agent. Antibacterial agent 154 inhibits Gram-positive and Gram-negative bacteria. Antibacterial agent 154 demonstrated in vivo efficacy in a mouse model of staphylococcal sepsis .

HY-P5206

Garvicin KS, GakB	Bacterial	Infection
Garvicin KS, GakB is a peptide at sizes of 34 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakA, and GakC. Garvicin KS, GakB inhibits fibroblast viability and proliferation. Garvicin KS, GakB with GakA, is a potent combination with good peptide stability, antimicrobial efficacy, and fibroblast viability/proliferation effects. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .

HY-146334

DFBTA	Chloride Channel	Inflammation/Immunology
DFBTA is an orally active, potent and little brain penetrated ANO1 (Calcium-activated chloride channel anoctamin-1) inhibitor, with an IC₅₀ of 24 nM. DFBTA shows analgesic efficacy for inflammatory pain .

HY-163544

δ-Tocotrienol prodrug-1	Others	Cancer
δ-Tocotrienol prodrug-1 (compound 5b) is a prodrug of δ-tocotrienol (HY-122778). δ-Tocotrienol prodrug-1 shows radioprotective efficacy. δ-Tocotrienol prodrug-1 promotes the hematopoietic progenitor and stem cell regeneration in murine bone marrow and spleen .

HY-146034

NOD1/2 antagonist-1	NOD-like Receptor (NLR)	Inflammation/Immunology Cancer
NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC₅₀ values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T_1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .

HY-123870

MX107	Survivin IAP NF-κB	Inflammation/Immunology Cancer
MX107 is a selective and potent survivin inhibitor that suppresses triple-negative breast cancer (TNBC) cell proliferation. MX107 induces degradation of survivin and inhibitor-of-apoptosis proteins (IAPs), which inhibits nuclear factor κB (NF-κB) activation induced by DNA damage. MX107 enhances tumoricidal efficacy of genotoxic treatments synergized with chemotherapeutic drugs .

HY-157516

CDK2-IN-22	CDK	Cancer
CDK2-IN-22 (compound 7I) is a potent CDK2 inhibitor with an IC₅₀ of 64.42 nM. CDK2-IN-22 presents a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC₅₀ values of 0.83 μM, 2.12 μM, 3.12 μM, and 8.61 μM, respectively .

HY-11044

PF-03654746 Tosylate	Histamine Receptor	Neurological Disease Inflammation/Immunology Endocrinology
PF-03654746 Tosylate is a potent and selective histamine H3 receptor antagonist with high brain penetration. PF-03654746 Tosylate reduces allergen-induced nasal symptoms . PF-03654746 Tosylate has potential for treatment of human cognitive disorders, improves cognitive efficacy and disease-modifying effects in Alzheimer's disease (AD) .

HY-146731

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

HY-110022

GW1929 hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .

HY-151561

WM382	Parasite	Infection
WM382 is an orally active and potent dual plasmepsin IX/X (PMIX/X) inhibitor with IC₅₀ values of 1.4 nM and 0.03 nM, respectively. WM382 has robust in vivo efficacy at multiple stages of the malaria parasite life cycle and an excellent resistance profile .

HY-148808

Zelasudil RXC007	ROCK	Cancer
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-15496

E6201 ER-806201	MEK FLT3	Cancer
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy .

HY-169001

5-HT2A/5-HT2C inverse agonist 1	5-HT Receptor	Neurological Disease
5-HT2A/5-HT2C inverse agonist 1 is a potent and dual 5-HT2A and 5-HT2C receptor inverse agonist with a hERG inhibitions, thus avoiding cardiovascular risks. 5-HT2A/5-HT2C inverse agonist 1 shows significant antipsychotic efficacy in the MK-801 (HY-15084B)-induced mouse model. 5-HT2A/5-HT2C inverse agonist 1 is promising for research of psychosis .

HY-121349

Aerothionin	Bacterial Fungal Antibiotic	Infection Cancer
Aerothionin is an antibiotic with potent antimicrobial efficacy against bacteria and fungi. Aerothionin exhibits antitumor efficacy against adrenal pheochromocytomas and extra-adrenal paragangliomas (PPGLs) .

HY-123287

Soquinolol	Adrenergic Receptor	Cardiovascular Disease
Soquinolol is a β adrenergic receptor antagonist. Soquinolol plays an important role in cardiac failure research .

HY-156249

NMS-P528	ADC Cytotoxin	Cancer
NMS-P528 is a Duocarmycin derivative that can be used as an ADC payload. NMS-P528 can be used to synthesize NMS-P945 .

HY-162785

XC219	CDK	Infection
XC219 (compound 43) is a cyclin-dependent kinase CDK) inhibitor, that covalently binds to CDK active site Lys. XC219 can be used in antifungal research .

HY-107085

Talmetacin	Others	Inflammation/Immunology
Talmetacin exhibits anti-inflammatory and analgesic efficacy .

HY-N0714A

Berbamine dihydrochloride 5+ Cited Publications	NF-κB Autophagy Apoptosis	Cancer
Berbamine dihydrochloride is an inhibitor of NF-κB activity with remarkable anti-myeloma efficacy.

HY-107032

Amitriptylinoxide Equilibrin	5-HT Receptor	Neurological Disease
Amitriptylinoxide (Equilibrin) is an analogue and metabolite of amitriptyline with similar antidepressant efficacy .

HY-163648

Suloxifen	Others	Inflammation/Immunology
Suloxifen is a thioketone compound, which exhibits anti-asthmatic efficacy .

HY-120943

K-111 BM 17.0744	PPAR	Metabolic Disease
K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome .

HY-13451

Finafloxacin 1 Publications Verification	Bacterial Antibiotic	Infection
Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments.

HY-13451A

Finafloxacin hydrochloride	Bacterial	Infection
Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments.

HY-153831

c-Met-IN-17	c-Met/HGFR	Cancer
c-Met-IN-17 is a potent c-Met kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-108235

Lanicemine AZD6765	iGluR	Neurological Disease
Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (K_i of 0.56-2.1 μM for NMDA receptor; IC₅₀s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .

HY-108235B

(Rac)-Lanicemine (Rac)-AZD6765	iGluR	Neurological Disease
(Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (K_i of 0.56-2.1 μM for NMDA receptor; IC₅₀s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .

HY-108235A

Lanicemine dihydrochloride AZD6765 dihydrochloride; ARL 15896AR	iGluR	Neurological Disease
Lanicemine (AZD6765) dihydrochloride is a low-trapping NMDA channel blocker (K_i of 0.56-2.1?μM for NMDA receptor; IC₅₀s of 4-7?μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .

HY-12421

BET-BAY 002	Epigenetic Reader Domain	Cancer
BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.

HY-107710

LY 233053	iGluR	Neurological Disease Inflammation/Immunology
LY 233053 is a potent and competitive NMDA-receptor antagonist with anticonvulsant and antiepileptic efficacy .

HY-161243

AChE-IN-56	Cholinesterase (ChE)	Neurological Disease
AChe-IN-56 is an orally active inhibitor for acetylcholinesterase enzyme (AChE) with neuroprotective efficacy .

HY-10233

Gaboxadol hydrochloride 1 Publications Verification Lu 02-030 hydrochloride; THIP hydrochloride	GABA Receptor	Neurological Disease
Gaboxadol hydrochloride (Lu 02-030 hydrochloride) is a potent agonist of the GABA_A receptor and an antagonist of GABA_C receptors (IC₅₀=25 μM). Gaboxadol hydrochloride displays a partial agonist efficacy on subunit α1β2γ2 with an ED₅₀ value of 143 μM, a full agonist efficacy at α5 subunit (ED₅₀=28-129 μM) and a superagonist efficacy at α4β3δ (ED₅₀=6 μM). Gaboxadol hydrochloride is a non-opioid agent .

HY-101096

Suvecaltamide MK-8998; CX-8998; JZP385	Calcium Channel	Neurological Disease Cancer
Suvecaltamide (MK-8998) is a selective T-type calcium channel inhibitor with oral efficacy. Suvecaltamide exhibits no cytotoxicity in myeloma cell lines and does not affect the antitumor efficacy of Bortezomib (BTZ). Suvecaltamide reverses BTZ-induced peripheral neuropathy (CIPN) in mouse and rat models, and helps inhibit myeloma growth .

Cat. No.	Product Name

HY-L098

Drug Metabolite Library

227 compounds

A drug metabolite is a byproduct of the body breaking down, or “metabolizing” a drug into a different substance. Most drugs undergo chemical alteration by various bodily systems as a way to create compounds that are more easily excreted from the body. Drugs can be metabolized by oxidation, reduction, hydrolysis, hydration, conjugation, condensation, or isomerization. Drug metabolism can produce metabolites with physicochemical and pharmacological properties that differ substantially from those of the parent drug, and consequently have important implications for both drug safety and efficacy.

MCE offers a unique collection of 227 drug metabolites which is a useful tool for drug safety and efficacy study and drug repurposing.

HY-L177

Antibody Inhibitor Library

913 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 913 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

HY-L061

Orally Active Compound Library

3,634 compounds

Most of the drugs that are available in the marketplace are administered via the oral route, which is a convenient and cost effective route of administration. Thus, oral bioavailability is one of the key considerations in drug design and development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity. A poor oral bioavailability can result in low efficacy and higher inter-individual variability and therefore can lead to unpredictable response to a drug. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market.

MCE offers a unique collection of 3,634 compounds with confirmed high oral bioavailability. MCE Orally Active Compound Library is a useful tool for discovering new drugs with oral bioavailability.

HY-L179

Radiosensitizer Library

40 compounds

Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.

MCE designs a unique collection of 40 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

HY-L022M

FDA-Approved Drug Library Mini

3,062 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.

MCE owns a unique collection of 3,062 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. The package of this library is 96-well microplate with peelable foil seal, which makes the screening process easier and faster.

HY-L170

Allosteric Modulators (AMs) Compound Library

183 compounds

An emerging drug design method is based on the secondary binding site effect, where small molecule drugs are designed to bind to secondary binding sites on target biomolecules rather than primary orthomorphic sites. Successful potential drugs (known as allosteric modulators) will be able to bind to allosteric sites and remotely alter (or modify) the conformation of the main orthosteric binding sites of biological targets. Allosteric modulators (AMs) are ligands of proteins that act through binding sites different from natural (orthosteric) ligand sites. AMs are relatively small, more lipophilic, and more rigid compounds. The binding efficacy of AMs with their targets is often slightly lower. AMs are divided into positive AMs (PAMs) and negative AMs (NAMs). AMs are ideal drug targets because they can fine-tune receptor activity while preserving the spatial and temporal signal transduction characteristics of endogenous ligands, resulting in fewer targeted side effects, improved subtype selectivity, and better promotion of biased signal transduction than normal ligands.

MCE designs a unique collection of 183 small allosteric modulators. It is a good tool to be used for research on metabolize, cancer and other diseases.

Cat. No.	Product Name	Type

HY-Y1903

Phosal 50 PG 3 Publications Verification	Co-solvents
Phosal 50 PG is a cosolvent (standardised phosphatidylcholine concentrate). Phosal 50 PG as a carrier for lipophilic compounds, can improve the absorption, efficacy and therapeutic index of the active ingredient .

HY-40156

5-Fluoroindole	Biochemical Assay Reagents
5-Fluoroindole is an antibacterial agent, that inhibits Mycobacterium tuberculosis with a MIC of 4.7 μM. 5-Fluoroindole exhibits metabolic stability in rat liver microsomes. 5-Fluoroindole exhibits anti-tuberculosis efficacy in mice .

HY-150097

Recombinant Human Serum Albumin(rHSA)	Native Proteins
Recombinant Human Serum Albumin (rHSA) is an active compound and possesses an identical conformation to plasma derived HSA. Recombinant Human Serum Albumin (rHSA) has no difference between rHSA and plasma derived HSA. Recombinant Human Serum Albumin (rHSA) has high efficacy of rHSA with little or no adverse reaction .

HY-151507

306Oi10

Drug Delivery

306Oi10 is a branched ionizable lipid that can be used to construct lipid nanoparticles (LNPs) for delivering messenger RNA. The surface ionization of lipid nanoparticles is related to the effectiveness of mRNA delivery. The tail of 306Oi10 has a one-carbon branch, which provides it with stronger surface ionization compared to lipids with linear tails, thereby enhancing its mRNA delivery efficacy. 306Oi10 can be used in research related to mRNA delivery .

HY-W250308

ε-Poly-L-lysine (MW 3800-4200)

Epsilon-polylysine (MW 3800-4200); ε-Polylysine (MW 3800-4200); ε-PL (MW 3800-4200)

Cell Assay Reagents

Epsilon-polylysine is an antimicrobial peptide that can be produced by bacteria such as Streptomyces. Epsilon-polylysine inhibits the growth of microorganisms such as bacteria, yeasts and molds and is therefore often used as a green food additive and preservative in various food and beverage products. Epsilon-polylysine has a variety of properties, including thermal stability, resistance to acidic conditions, and broad-spectrum antimicrobial activity. Epsilon-polylysine can be loaded on other materials to form nanoparticles or form nanofiber membranes for targeted delivery to exert sustained antibacterial efficacy. Epsilon-polylysine is also used as a liposome stabilizer .

HY-W250308A

ε-Poly-L-lysine hydrochloride (MV 2000-5000)

Epsilon-polylysine hydrochloride (MV 2000-5000); ε-Polylysine hydrochloride (MV 2000-5000); ε-PL hydrochloride (MV 2000-5000)

Cell Assay Reagents

ε-Poly-L-lysine hydrochloride (MV 2000-5000) is an antimicrobial peptide that can be produced by bacteria such as Streptomyces. Epsilon-polylysine hydrochloride inhibits the growth of microorganisms such as bacteria, yeasts and molds and is therefore often used as a green food additive and preservative in various food and beverage products. Epsilon-polylysine hydrochloride has a variety of properties, including thermal stability, resistance to acidic conditions, and broad-spectrum antimicrobial activity. Epsilon-polylysine hydrochloride can be loaded on other materials to form nanoparticles or form nanofiber membranes for targeted delivery to exert sustained antibacterial efficacy. Epsilon-polylysine hydrochloride is also used as a liposome stabilizer .

HY-144002

RIBI-529 RC-529	Drug Delivery
RIBI-529 (RC-529), a lipid A mimetic (aminoalkyl glucosaminide 4-phosphate), is a adjuvant with a similar efficacy to MPL (Corixa). RIBI-529 signals through Toll-like receptor 4 to stimulate the innate immune system .

HY-15401A

WAY 163909 hydrochloride

Biochemical Assay Reagents

WAY-163909 hydrochloride is a potent 5-hydroxytryptamine receptor 2C (5-HT2C) agonist with an EC50 of 8 nM and a maximum efficacy of 90%, while displaying minimal activity at 5-HT2A receptors. Its selectivity is further demonstrated by Ki values of 10.5 nM for 5-HT2C, alongside higher Ki values for 5-HT2A (212 nM), 5-HT7 (343 nM), and 5-HT2B (485 nM), and it lacks significant activity at various other receptors.

Cat. No.	Product Name	Target	Research Area

HY-P2341

Angiopep-2 hydrochloride	Peptides	Cancer
Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer .

HY-P10233A

SAAP 148 TFA	Bacterial	Infection
SAAP 148 TFA is an antimicrobial and antibiofilm agent, and exhibits inhibitory efficacy against antibiotic-resistant pathogens, with LC₅₀ of 0.8-12.8 μM .

HY-P5206

Garvicin KS, GakB	Bacterial	Infection
Garvicin KS, GakB is a peptide at sizes of 34 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakA, and GakC. Garvicin KS, GakB inhibits fibroblast viability and proliferation. Garvicin KS, GakB with GakA, is a potent combination with good peptide stability, antimicrobial efficacy, and fibroblast viability/proliferation effects. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .

HY-125745

Loloatin B 10	Antibiotic Bacterial	Infection
Loloatin B 10 is an antibiotic, which exhibits antibacterial efficacy against gram positive antibiotic resistant human pathogens .

HY-P1615

Cenupatide	Peptides	Cancer
Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy .

HY-P2374

Ac-DMQD-CHO	Caspase Apoptosis	Neurological Disease
Ac-DMQD-CHO is a selective inhibitor for caspase 3, with IC₅₀ of 39 nM. Ac-DMQD-CHO reduces apoptosis, and exhibits neuroprotective efficacy .

HY-P10233

SAAP 148	Bacterial	Infection
SAAP 148 is an antimicrobial and antibiofilm agent, and exhibits inhibitory efficacy against antibiotic-resistant pathogens, with LC₅₀ of 0.8-12.8 μM .

HY-19648

Ebiratide HOE-427 free base	Peptides	Neurological Disease
Ebiratide (HOE-427 free base) is a synthesized ACTH derivative, which acts directly on the central nervous system and exhibits memory-enhancing efficacy .

HY-P10255

K90-114TAT	Potassium Channel	Cancer
K90-114TAT is an inhibitor for EAG2-Kvβ2 interaction, and exhibits antitumor efficacy against glioblastomas .

HY-P0090A

Calcitonin (salmon) (acetate) Salmon calcitonin acetate	CGRP Receptor	Cancer
Calcitonin (salmon) (acetate) is a dual-action amylin and calcitonin receptor agonist, can stimulate bone formation and inhibit bone resorption .The acetate form can affect the absorption and efficacy of hormones .

HY-P10239

Tyr3-Octreotate	Peptides	Cancer
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy .

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Peptides	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .

HY-162396

P-gp inhibitor 21	P-glycoprotein	Cancer
P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .

HY-P10431

Hc-CATH Sea snake cathelicidin	Bacterial	Infection Inflammation/Immunology
Hc-CATH (Sea snake cathelicidin) is an antibacterial peptide with broad-spectrum. Hc-CATH inhibits Shigella dysenteriae and Klebsiella pneumoniae with MIC of 0.16 mM-20.67 mM. Hc-CATH exhibits anti-inflammatory efficacy .

HY-P2381

TRV120055 1 Publications Verification	Peptides	Others
TRV120055 is a G_q-biased agonists, exhibits 10-fold larger molecular efficacies at the AT₁R-Gq fusion protein compared with the AT₁R-βarr2 fusion protein .

HY-P2382

TRV120056	Peptides	Others
TRV120056 is a G_q-biased agonists, exhibits 10-fold larger molecular efficacies at the AT₁R-Gq fusion protein compared with the AT₁R-βarr2 fusion protein .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P10498

[Des-Tyr1]-gamma-Endorphin	Peptides	Neurological Disease
[Des-Tyr1]-gamma-Endorphin is a neuropeptide, which can be found in human cerebrospinal fluid. [Des-Tyr1]-gamma-Endorphin exhibits antidepressant efficacy, facilitates the extinction of active avoidance and attenuates the passive avoidance behavior in rats .

HY-P1351

Angiopep-2-Cys	Peptides	Cancer
Angiopep-2-cys is a conjugate of Angiopep-2 hydrochloride (HY-P2341) and cysteine. Angiopep-2 hydrochloride is a brain peptide vector. The conjugation of anticancer agents with the Angiopep-2 peptide vector could increase their efficacy in the treatment of brain cancer .

HY-P1253

α-Endorphin (human)	Opioid Receptor	Neurological Disease
α-Endorphin (human) is a neuropeptide, that acts on the central nervous system (CNS) and peripheral nervous system (PNS). α-Endorphin (human) binds μ-opioid receptor, and exhibits analgesic efficacy. α-Endorphin (human) regulates sexual behaviors and pleasure felling .

HY-P10235

Cyclic AC253	Amylin Receptor	Neurological Disease
Cyclic AC253 is an antagonist for amylin receptor, with IC₅₀ of 0.3 μM. Cyclic AC253 exhibits neuroprotective efficacy against Aβ toxicity and abrogates Aβ-induced impairment of hippocampal long-term potentiation. Cyclic AC253 penetrate blood-brain barrier (BBB) .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-122357

Bestim	Adenylate Cyclase	Inflammation/Immunology
Bestim is a dipeptide, which exhibits high affinity to murine peritoneal macrophages, thymocytes, and plasma membranes isolated from these cells, with K_ds of 3.1, 2.1, 18.6 and 16.7 nM, respectively. Bestim inhibits adenylate cyclase in the membranes of murine macrophages and thymocytes. Bestim exhibits immunomodulatory efficacy .

HY-P1711

L 366763	Peptides	Cardiovascular Disease
L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P2428

RI-61	Peptides	Neurological Disease
RI-61 is a compound that has activity in suppressing migraine, cluster headache, new daily persistent headache and cyclical vomiting syndrome. RI-61 has shown significant efficacy in relieving the symptoms of these disorders. RI-61 helps relieve pain and other related symptoms by modulating the action of neurotransmitters .

HY-P3350

LS-BF1	Bacterial	Infection
LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].

HY-149205

CXJ-2	PI3K ERK	Inflammation/Immunology
CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy .

HY-N6693

Valinomycin 3 Publications Verification NSC 122023	Apoptosis Antibiotic Autophagy Fungal	Infection Others Cancer
Valinomycin is a potassium-specific ionophore, the valinomycin-K ⁺ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K ⁺ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .

HY-P10439

CVRARTR	PD-1/PD-L1	Cancer
CVRARTR is an antagonist for programmed cell death ligand-1 (PD-L1) with K_D of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model .

HY-P1640

(Trp63,Trp64)-C3a(63-77)	Complement System	Inflammation/Immunology
(Trp63,Trp64)-C3a(63-77) is a C3a synthetic analogue peptide, which exhibits Ca ²⁺ stimulating efficacy in human neutrophils and hC3aR or mC3aR expressing RBL-2H3 cells with EC₅₀ of 9.5, 2.0 and 0.8 nM, respectively .

HY-P5205

Garvicin KS, GakA	Bacterial	Infection
Garvicin KS, GakA is a peptide at sizes of 34 amino acids to form bacteriocin garvicin KS (GarKS), with other 2 peptides, GakB, and GakC. Garvicin KS, GakA inhibits fibroblast viability and proliferation. Garvicin KS, GakA with GakB, is a potent combination with good peptide stability, antimicrobial efficacy, and fibroblast viability/proliferation effects. Garvicin KS peptides inhibit MSSA with MIC values in the order GakB >GakC >GakA .

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), HDAC3 (IC₅₀=9.18 nM), HDAC6 (IC₅₀=42.7 nM), HDAC8 (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy .

HY-16381

Pasireotide 5 Publications Verification SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381A

Pasireotide acetate 5 Publications Verification SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pK_i=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-14743

Golotimod SCV 07; Gamma-D-glutamyl-L-tryptophan	Bacterial STAT	Infection Inflammation/Immunology Cancer
Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) .

HY-P3641

Kisspeptin 13	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P10490

(D-His(Bzl)6)-LHRH (1-7) (free acid)	Peptides	Others Cancer
(D-His(Bzl)6)-LHRH (1-7) free acid is a synthetic peptide compound that is a derivative of luteinizing hormone-releasing hormone (LHRH). (D-His(Bzl)6)-LHRH (1-7) free acid enhances its stability and biological activity by introducing unnatural amino acid residues at specific positions of the LHRH molecule. This modification can improve the drug's performance in the body half-life, reducing the rate at which it is rapidly metabolized and cleared, thereby enhancing its efficacy in inhibiting cell proliferation .

HY-P5295

Cy3-Ova (323-339)	Peptides	Others
Cy3-Ova (323-339) is an Cy3 labled OVA Peptide (323-339) (HY-P0286). Cy3 is a fluorescent dye belonging to the Cyanine family and is a fluorescent light product of Cy5. Cyanine is commonly used in fluorescence microscopy, cell imaging, and molecular biology experiments. OVA Peptide (323-339) represents the T and B cell epitopes of ovalbumin (OVA). OVA Peptide (323-339) has limited immunogenic efficacy in activating OVA-sensitized and attacked mouse spleen cells .

HY-156002

LUNA18	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

HY-P3641A

Kisspeptin 13 TFA	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-P0117A

Tat-NR2B9c TFA Maximum Cited Publications 8 Publications Verification Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-P0117

Tat-NR2B9c Maximum Cited Publications 8 Publications Verification Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits?neuronal nitric oxide synthase (nNOS)/PSD-95?interaction, and possesses neuroprotective efficacy .

Cat. No.	Product Name	Target	Research Area

HY-P99103

Bebtelovimab LY-3853113; LY-COV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

HY-P99273

Vorsetuzumab	Inhibitory Antibodies	Cancer
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .

HY-P990083

Tegoprubart	Inhibitory Antibodies	Cancer
Tegoprubart is a monoclonal antibody directed against CD40 ligand (CD40L), a key mediator of costimulation. Inhibition of CD40L reduces cellular and antibody-mediated immunity and creates a more tolerant immune environment. Tegoprubart was demonstrated to have in vivo efficacy in transplantation animal models.

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	MMP	Cancer
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-P99412

Lusvertikimab OSE-127	Interleukin Related	Cancer
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .

HY-108847

Etanercept 5+ Cited Publications	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-P99579

Tamtuvetmab AT-005; AT005	Inhibitory Antibodies	Cancer
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-P99342

Imdevimab REGN10987	SARS-CoV	Infection
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-P99493

Cantuzumab ravtansine IMGN242; huC242-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-P99492

Cantuzumab mertansine SB-408075; huC242-DM1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0714A

Berbamine dihydrochloride 5+ Cited Publications	Alkaloids Structural Classification Monophenols other families Classification of Application Fields Source classification Phenols Plants Isoquinoline Alkaloids Disease Research Fields Cancer	NF-κB Autophagy Apoptosis
Berbamine dihydrochloride is an inhibitor of NF-κB activity with remarkable anti-myeloma efficacy.

HY-13451

Finafloxacin 1 Publications Verification	Microorganisms Source classification	Bacterial Antibiotic
Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments.

HY-W013372

7,8-Dihydroxyflavone 10+ Cited Publications	Structural Classification Flavonoids Flavones Source classification Phenols Polyphenols Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray	Trk Receptor Apoptosis
7,8-Dihydroxyflavone is a potent and selective TrkB agonist that mimics the physiological actions of Brain-derived neurotrophic factor (BDNF). Displays therapeutic efficacy toward various neurological diseases .

HY-W015820

Phthalide	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	Bacterial
Phthalide is a promising chemical scaffold with a potent anti-inflammatory efficacy. Phthalide can be used to synthesize a variety of phthalide derivatives including anti-inflammatory agent, antimicrobial, antioxidant .

HY-121349

Aerothionin	Structural Classification Antibiotics Marine natural products Source classification Sponge	Bacterial Fungal Antibiotic
Aerothionin is an antibiotic with potent antimicrobial efficacy against bacteria and fungi. Aerothionin exhibits antitumor efficacy against adrenal pheochromocytomas and extra-adrenal paragangliomas (PPGLs) .

HY-121592

Yokonoside	Structural Classification Cardiacglycosides Ranunculaceae Source classification Plants Aconitum japonicum Thunberg Steroids	Endogenous Metabolite
Yokonoside is a cardiac glycoside, which can be isolated from Aconitum japonicum. Yokonoside exhibits antioxidant efficacy .

HY-N12398

Psychotridine	Structural Classification Alkaloids Source classification Psychotria forsteriana A.Gray Rubiaceae Plants Indole Alkaloids	Others
Psychotridine is a natural alkaloid isolated from Psychotria colorata, reveals an analgesic activity in nervous system and an inhibitory efficacy towards platelet aggregation .

HY-N12711

Calycosin 7-O-xylosylglucoside	Structural Classification Flavonoids Flavones Leguminosae Source classification Sophora flavescens Aiton Plants	Others
Calycosin 7-O-xylosylglucoside exhibits hepatoprotective efficacy in human hepatic cell HL-7702 through scavenging oxidative damage and antioxidant properties .

HY-N7546

Agavoside C'	Structural Classification Agave americana Linn. Polysaccharides Source classification Agavaceae Plants Saccharides	Others
Agavoside C' is a tetraglycoside, which can be isolated from concentrated agave sap. Agavoside C' exhibits antineoplastic efficacy, contributes to necrosis induction with an IC₅₀ of 108 μg/mL .

HY-120885

(+)-Oxanthromicin	Structural Classification Microorganisms Source classification Phenols Polyphenols	Ras
(+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy .

HY-N2138

Buddlejasaponin IVb	Triterpenes Prosopis juliflora (Sw.) DC. Classification of Application Fields Terpenoids Labiatae Dipsacaceae Source classification Plants Dipsacus asper Inflammation/Immunology Disease Research Fields	Others
Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .

HY-P9989

Linvoseltamab REGN5458	Classification of Application Fields Disease Research Fields Cancer	CD3 TNF Receptor
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

HY-N11896A

10-Hydroxyaloin A	Structural Classification Natural Products Liliaceae Source classification Aloe vera (L.) Burm. f. Plants	SARS-CoV
10-10-Hydroxyaloin A is potent SARS-CoV-2 inhibitor. 10-Hydroxyaloin A exhibits significant efficacy to bind SARS-Cov-2 M_pro active site .

HY-125698

3-Deoxyaphidicolin	Structural Classification Natural Products Microorganisms Source classification	Parasite
3-Deoxyaphidicolin exhibits phytotoxic efficacy, that inhibits root growth of lettuce seedlings. 3-Deoxyaphidicolin also exhibits leishmanicidal activity against Leishmania major and Leishmania braziliensis .

HY-114969

Clioxanide NSC 233846; SYD 230; Tremerad	Structural Classification Natural Products Animals Source classification	Parasite
Clioxanide is a potential anti-liver fluke (Fasciola hepatica) agent. The results showed that Clioxanide showed no efficacy against 4-week-old or 19-week-old flukes at doses of 135 mg/kg or 200 mg/kg. In contrast, hexachloroethane was very effective against older flukes, reaching 100% efficacy at lower doses. The study pointed out that laboratory mice may not be suitable for screening potential compounds against liver fluke infections in ruminants such as cattle and sheep. In addition, no obvious toxic reactions were observed in mice with Clioxanide .

HY-B0997R

Hydroquinidine (Standard)	Alkaloids Structural Classification Source classification Rubiaceae Cinchona calisaya Wedd. Quinoline Alkaloids Plants	Others
Hydroquinidine (Standard) is the analytical standard of Hydroquinidine. This product is intended for research and analytical applications. Hydroquinidine (Dihydroquinidine) is a derivative of Quinidine (an antiarrhythmic agent). Hydroquinidine prolongs the QT interval and has antiarrhythmic efficacy .

HY-114803

Kokusaginine	Structural Classification Alkaloids Source classification Rutaceae Quinoline Alkaloids Melicope pteleifolia (Champ. ex Benth.) Hartley Plants	Cholinesterase (ChE) Apoptosis Microtubule/Tubulin
Kokusaginine is a furoquinoline alkaloids, which exhibits inhibitory efficacy for acetylcholinesterase (AChE) with an IC₅₀ of 28.2 μM. Kokusaginine exhibits anti-proliferative and apoptotic inducing effects in MCF-7/ADR cells .

HY-B0997

Hydroquinidine Dihydroquinidine; (+)-Hydroquinidine; Hydroconquinine	Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Rubiaceae Cinchona calisaya Wedd. Quinoline Alkaloids Plants Disease Research Fields	Others
Hydroquinidine (Dihydroquinidine) is a potent ion channel blocker, which exhibits strong anti-cancer activity on colon, pancreatic, and hepatocellular cancer cells. Hydroquinidine prolongs the QT interval and has antiarrhythmic efficacy .

HY-N6707

Triacsin C 3 Publications Verification WS 1228A; FR 900190	Infection Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	Parasite
Triacsin C (WS 1228A), a natural intracellular long-chain acyl-CoA synthetases (ACSL) inhibitor, is from Streptomyces aureofaciens. Triacsin C inhibits TAG accumulation into lipid droplets (LD) by suppressing ACSL activity . Triacsin C is found to be highly effective against rotavirus replication .

HY-122365

Inositol nicotinate Inositol niacinate; Hexanicit	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Others
Inositol nicotinate (Hexanicit) has vasodilating effects and can be used in research on peripheral arterial disease, showing efficacy when taken orally. Inositol nicotinate does not significantly improve triglyceride levels in mice induced by biphenyl esters .

HY-N9588

Pedaliin	Flavonoids Sesamum indicum Linn. Pedaliaceae Plants Isoflavones	Others
Pedaliin is a bioactive component obtained from the ethanol extract of Sesame (Sesamum indicum L.) leaves (SLs). Pedaliin shows in vitro antioxidant and anti-colon cancer efficacy with radical scavenging activity and ferric reducing antioxidant power (FRAP) .

HY-N8342

Rhamnazin	Structural Classification Combretaceae Source classification Phenols Polyphenols Plants Combretum erythrophyllum Sond.	VEGFR
Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC₅₀ of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .

HY-N2412

Irisolidone	Structural Classification Neurological Disease Classification of Application Fields Source classification Pueraria lobata (Willd.) Ohwi var. montana (Lour.)van der Maesen Plants Flavonoids Leguminosae Phenols Polyphenols Disease Research Fields Isoflavones Cancer	Chloride Channel
Irisolidone is a major isoflavone found in Pueraria lobata flowers. Irisolidone exhibits potent hepatoprotective activity. Irisolidone shows the high efficacy for volume-regulated anion channels (VRAC) blockade (IC₅₀=9.8 μM) .

HY-121104

Bactobolin	Structural Classification Natural Products Microorganisms Source classification	Antibiotic Bacterial
Bactobolin is an antibiotic, which inhibits Escherichia coli, Salmonella, Shigella, Staphylococcus and Bacillus subtilis, with MICs of 0.3-6.25 μg/mL. Bactobolin exhibits antitumor efficacy against leukemia, with LD₅₀ of 6.25-12.5 mg/kg .

HY-130398

Aerophobin-2	Structural Classification Natural Products Marine natural products Source classification Sponge	α-synuclein
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-N7778

3-Hydroxy-(28-4-coumaroyloxy)lup-20(29)-en-27-oic acid	Triterpenes Structural Classification Terpenoids Source classification Caraipa densifolia Mart. Plants Calophyllaceae	Others
3-Hydroxy-(28-4-coumaroyloxy)lup-20(29)-en-27-oic acid is a derivative of lupene, which can be isolated from Caraipa densifolia. Caraipa densifolia Extracts exhibits anticancer efficacy .

HY-114977

Avenanthramide A	Structural Classification Avena sativa Linn. Gramineae Source classification Phenols Polyphenols Plants	Reactive Oxygen Species Apoptosis
Avenanthramide A is a phytoalexin, which can be found in oats (Avena sativa L.). Avenanthramide A targets the RNA helicase DDX3, leads to mitochondrial swelling and increased ROS production, and induces apoptosis in CRC cells. Avenanthramide A exhibits antitumor efficacy in mouse model. Avenanthramide A orally active .

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	Classification of Application Fields Disease Research Fields Cancer	MMP
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Structural Classification Animals Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields Cancer	Others
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-129331

Neothramycin A	Structural Classification Microorganisms Antibiotics Source classification	Antibiotic Bacterial Fungal
Neothramycin A is an antibiotic, which can be isolated from Streptomyces. Neothramycin A exhibits board spectrum antimicrobial activity, inhibits Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli W677, and Saccharomyces cerevisia with MIC of 25-50 μg/mL. Neothramycin A exhibits antitumor efficacy against leukemia in mouse models .

HY-125524

Antibacterial agent 199	Structural Classification Natural Products Microorganisms Source classification	Bacterial
Antibacterial agent 199 (Compound 2) is an activator for caseinolytic protease (ClpP) with a K_d of 0.7 μM. Antibacterial agent 199 exhibits antibacterial efficacy against Gram-positive strains Staphylococcus aureus, Streptococcus pneumoniae and Gram-negative strain Neisseria meningitidis, with MICs of 16, 0.5 and 0.5 μg/mL, respectively .

HY-119741

Salacinol	Structural Classification Natural Products Source classification Salacia reticulata Wight Celastraceae Plants	Lipase
Salacinol can be isolated from the roots of the plant Salacia reticulata. Salacinol inhibits fat metabolizing enzymes, such as pancreatic lipase (PL, IC₅₀=12.6 mg/L), lipoprotein lipase (LPL, IC₅₀=13.6 mg/L), and glycerophosphate dehydrogenase (GPDH), enhances the lipolysis, and exhibits antiobesity efficacy in rats .

HY-19543

Brusatol Maximum Cited Publications 27 Publications Verification NSC 172924	Structural Classification Simaroubaceae Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Disease Research Fields Brucea javanica (L.) Merr. Cancer	Keap1-Nrf2 Apoptosis
Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent . Brusatol increases cellular apoptosis .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-113829

Valnemulin	Structural Classification Natural Products Animals Source classification	Antibiotic Bacterial
Valnemulin is an orally active broad-spectrum antibiotic against Gram-negative and Gram-positive bacteria, anaerobic bacteria, Mycoplasma, and Spirochetes. Valnemulin ameliorates enteric diseases, acute polyarthritis and enzootic pneumonia in pigs . Valnemulin exhibits anti-inflammatory efficacy against lipopolysaccharide (HY-D1056)-induced lung injury .

HY-A0019

Paliperidone 2 Publications Verification 9-Hydroxyrisperidone	Structural Classification Natural Products Source classification Endogenous metabolite	Drug Metabolite Dopamine Receptor 5-HT Receptor Adrenergic Receptor
Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia .

HY-114977R

Avenanthramide A (Standard)	Structural Classification Avena sativa Linn. Gramineae Source classification Phenols Polyphenols Plants	Reactive Oxygen Species Apoptosis
Avenanthramide A (Standard) is the analytical standard of Avenanthramide A. This product is intended for research and analytical applications. Avenanthramide A is a phytoalexin, which can be found in oats (Avena sativa L.). Avenanthramide A targets the RNA helicase DDX3, leads to mitochondrial swelling and increased ROS production, and induces apoptosis in CRC cells. Avenanthramide A exhibits antitumor efficacy in mouse model. Avenanthramide A orally active .

HY-111827

S-1-Propenyl-L-cysteine 4 Publications Verification	Cardiovascular Disease Structural Classification Liliaceae Classification of Application Fields Ketones, Aldehydes, Acids Source classification Allium sativum Linn. Plants Disease Research Fields	Histamine Receptor
S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model . S-1-Propenyl-L-cysteine exhibits antioxidative efficacy through a NO-dependent BACH1 signaling pathway . S-1-Propenyl-L-cysteine is orally active.

HY-N1457

Chrysosplenetin	Flavonols Structural Classification Piscidia erythrina L. Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Compositae Disease Research Fields	P-glycoprotein Cytochrome P450 Ferroptosis
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits P-gp activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat CYP3A .

HY-125620

Rubiginone D2	Quinones Structural Classification Microorganisms Anthraquinones Source classification	Antibiotic Bacterial
Rubiginone D2 is an antibiotic, which exhibits antimicrobial activities against Bacillus subtilis, Staphylococcus aureus and Escherichia coli. Rubiginone D2 exhibits antitumor efficacy, inhibits proliferations of cancer cells HM02, Kato III, HepG2 and MCF7, with GI₅₀s of 0.1, 0.7, <0.1 and 7.5 μM, respectively .

HY-N6693

Valinomycin 3 Publications Verification NSC 122023	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Apoptosis Antibiotic Autophagy Fungal
Valinomycin is a potassium-specific ionophore, the valinomycin-K ⁺ complex can be incorporated into biological bilayer membranes with the hydrophobic surface of valinomycin, destroys the normal K ⁺ gradient across the membrane, and as a result kills the cells, incorporating into liposomes can significantly reduces the cytotoxicity and enhances the targeting effect. Valinomycin exhibits antibiotic, antifungal, antiviral, antitumor and insecticidal efficacy, thus can be used for relevant research .

HY-N12044

Asparanin A	Structural Classification Polysaccharides Liliaceae Source classification Plants Saccharides Asparagus officinalis L.	Apoptosis
Asparanin A is an apoptosis inducer with anticancer activity. Asparanin A induces cell cycle arrest in the G0/G1 phase through mitochondria and PI3K/AKT signaling pathways, inhibiting cancer cell growth. Asparanin A also demonstrated in vivo efficacy in a mouse xenograft model of Ishikawa endometrial carcinoma, significantly inhibiting tumor growth .

HY-B1671

(+)-Kavain	Structural Classification Source classification Other Phenylpropanoids Piper methysticum G.Forst. Piperaceae Phenylpropanoids Plants	GABA Receptor Sodium Channel Calcium Channel
(+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na ⁺ and Ca ²⁺ channels . (+)-Kavain is shown to bind at the α4β2δ GABA_A receptor and potentiate GABA efficacy . (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied .

HY-N2453

Convallatoxin	Triterpenes Structural Classification Classification of Application Fields Terpenoids Ranunculaceae Adonis amurensis Regel et Radde Plants Inflammation/Immunology Disease Research Fields	PPAR NF-κB P-glycoprotein
Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .

HY-A0019R

Paliperidone (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Drug Metabolite Dopamine Receptor 5-HT Receptor Adrenergic Receptor
Paliperidone (Standard) is the analytical standard of Paliperidone. This product is intended for research and analytical applications. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia .

HY-N4118

Cephaeline 1 Publications Verification (-)-Cephaeline; NSC 32944 free base	Infection Alkaloids Structural Classification Monophenols other families Classification of Application Fields Source classification Phenols Plants Isoquinoline Alkaloids Disease Research Fields	Filovirus Flavivirus Keap1-Nrf2 Ferroptosis Reactive Oxygen Species
Cephaeline ((-)-Cephaeline), a desmethyl analog of Emetine, is a phenolic alkaloid in Indian Ipecac roots isolated from the Cephaelis ipecacuanha. Cephaeline exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections. Cephaeline is an inductor of histone H3 acetylation and an inhibitor of mucoepidermoid carcinoma cancer stem cells (MEC), which promotes ferroptosis by inhibiting NRF2 to exert anti-lung cancer efficacy .

HY-B0796

Bismuth potassium citrate 20+ Cited Publications Bismuth tripotassium dicitrate; Bismuth subcitrate	Classification of Application Fields Disease Research Fields Cancer	Bacterial
Bismuth potassium citrate (Bismuth tripotassium dicitrate) is an orally active gastric mucosal protector and has antibacterial and anti-inflammatory activity. Bismuth potassium citrate relieves stomach pain, resists H. pylori growth and repairs gastric mucosa. Bismuth potassium citrate combined with Omeprazole (HY-B0113) has a safe and high efficacy against H. pylori infection, which is promising for research of peptic ulcers, gastric cancer and tubulointerstitial nephritis .

HY-135646

Eleutheroside B1	other families Classification of Application Fields Source classification Coumarins Phenylpropanoids Plants Disease Research Fields Inflammation/Immunology	Influenza Virus
Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human influenza virus efficacy, with an IC₅₀ value of 64-125 µg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti-inflammatory activities .

HY-126170

Valanimycin	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Antibiotic Bacterial
Valanimycin is an antibiotic, which inhibits Escherichia coli (BE1121) through interaction with DNA. Valanimycin exhibits cytotoxicity to mouse leukemia L1210, P388/S (doxorubicin (HY-15142A)-sensitive), and P388/ADR (doxorubicin-resistant), with IC₅₀ of 0.79, 2.65, and 1.44 μg/mL, respectively. Valanimycin exhibits antitumor efficacy against ehrlich ascites tumors or L1210 in mice .

HY-N12124

Monascuspiloin Monascinol	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Akt mTOR AMPK Androgen Receptor Apoptosis Autophagy
Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC₅₀ of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC₅₀ of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of Akt/mTOR signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice .

Cat. No.	Product Name	Chemical Structure

HY-13636S

Fulvestrant-d3
Fulvestrant-d₃ is the deuterium labeled Fulvestrant. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy[1].

HY-B0631S

Alendronic acid-d6
Alendronic acid-d₆ is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-119900S

Carnidazole-d3
Carnidazole-d3 is deuterium labeled Carnidazole (HY-119900). Carnidazole exhibits antiprotozoal efficacy against Trichomonas gallinae .

HY-B0647S1

Butylphthalide-d3
Butylphthalide-d₃ is the deuterium labeled Butylphthalide. Butylphthalide(3-n-Butylphthalide), an anti-cerebral-ischemia agent, is first isolated from the seeds of celery and showes efficacy in animal models of stroke.

HY-117727S

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

HY-B0126S

Marbofloxacin-d8
Marbofloxacin-d₈ is the deuterium labeled Marbofloxacin. Marbofloxacin is a third generation fluoroquinolone and orally active antimicrobial agent, which has a broad spectrum bactericidal activity and good efficacy. Marbofloxacin can be used for the research of infections by Gram-positive and Gram-negative bacteria and Mycoplasma[1][2][3].

HY-W009204S5

Fmoc-Ala-OH-13C3
Fmoc-Ala-OH- ¹³C₃ is a ¹³C-labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-ind

HY-111613S

Pinaverium bromide-d4
Pinaverium bromide-d₄ is deuterium labeled Pinaverium bromide. Pinaverium bromide is an L-type calcium channel blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients[1].

HY-101064S1

Fmoc-leucine-13C6,15N
Fmoc-leucine- ¹³C₆, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity

HY-108974S

Drotaverine-d10 hydrochloride

Drotaverine-d₁₀ (hydrochloride) is the deuterium labeled Drotaverine hydrochloride. Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine hydrochloride exhibits in vivo antispasmodic efficacy without anticholinergic effects[1][2].

HY-106901AS

Asoxime-d4 dichloride
Asoxime-d₄ (dichloride) is the deuterium labeled Asoxime dichloride. Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system[1].

HY-101064S2

Fmoc-leucine-d3
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

HY-101064S3

Fmoc-leucine-d10
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

HY-14852S

Tafamidis-d3
Tafamidis-d₃ is deuterium labeled Tafamidis. Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis[1].

HY-14262S1

Vilazodone-d8 hydrochloride
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-W757743

Acalabrutinib-d3
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-A0019S

Paliperidone-d4
Paliperidone-d₄ is the deuterium labeled Paliperidone. Paliperidone (9-Hydroxyrisperidone), the major active metabolite of Risperidone, is a dopamine D2 antagonist and 5-HT2A antagonist. Paliperidone is also active as an antagonist at α1 and α2 adrenergic receptors and H1-histaminergic receptors. Paliperidone, a antipsychotic agent, shows efficacy against schizophrenia[1].

HY-12390S

Lofepramine-d3

Lofepramine-d₃ (Lopramine-d3) is the deuterium labeled Lofepramine. Lofepramine (Lopramine) is a potent tricyclic antidepressant and is extensively metabolised to Desipramine. The antidepressant activity of Lofepramine stems from the facilitation of noradrenergic neurotransmission by uptake inhibition. Lofepramine may also potentiate serotoninergic neurotransmission by inhibition of the neuronal uptake of serotonin and the enzyme tryptophan pyrrolase. Lofepramine has significant anxiolytic efficacy in addition to its antidepressant properties[1].

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

Cat. No.	Product Name		Classification

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-134813

MRTX1133 10+ Cited Publications		Alkynes
MRTX1133 is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .

HY-168262

Antitrypanosomal agent 22		Alkynes
Antitrypanosomal agent 22 (compound 13) is a nitrothienylazine compound with trypanosomaticidal efficacy. Antitrypanosomal agent 22 shows leishmanicidal and trypanocidal with in vitro submicromolar activities, and devoid of toxicity on mammalian cells are uncovered .

HY-153831

c-Met-IN-17		Alkynes
c-Met-IN-17 is a potent c-Met kinase inhibitor with an IC₅₀ of 0.031 μM. c-Met-IN-17 can be used in anticancer research. . c-Met-IN-17 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163785

1"-α-Azido-RDPr		Azide
1"-α-Azido-RDPr (Compound 11) is an analog of adenosine diphosphate ribose, and exhibits inhibitory efficacy against the SARS-CoV-2 nonstructural protein macodomain SARS-CoV-2 NSP3 Mac1 with an IC₅₀ of 30 nM .

HY-159119

hDHODH-IN-15		Alkynes
hDHODH-IN-15 (Compound H19) is an inhibitor for human dihydroguanylate dehydrogenase (hDHODH) with an IC₅₀ of 0.21 µM. hDHODH-IN-15 exhibits cytotoxicity in cancer cells NCI-H226, HCT-116, and MDA-MB-231, with IC₅₀ of 0.95-2.81 µM. hDHODH-IN-15 induces ferroptosis in HCT-116, and exhibits antitumor efficacy .

Cat. No.	Product Name		Classification

HY-147079A

Egaptivon pegol sodium ARC 1779 sodium		Aptamers
Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium has anti-thrombotic efficacy.

HY-115567

5-NIdR 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole		Nucleosides and their Analogs
5-NIdR (1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole), an artificial nucleoside, exhibits the ability to inhibit the replication of DNA lesions generated by Temozolomide (HY-17364). 5-NIdR induces cancer cells apoptosis and arrests cell cycle at G0 phase. 5-NIdR enhances Temozolomide anti-tumor efficacy in murine glioblastoma model .

HY-151507

306Oi10		Cationic Lipids
306Oi10 is a branched ionizable lipid that can be used to construct lipid nanoparticles (LNPs) for delivering messenger RNA. The surface ionization of lipid nanoparticles is related to the effectiveness of mRNA delivery. The tail of 306Oi10 has a one-carbon branch, which provides it with stronger surface ionization compared to lipids with linear tails, thereby enhancing its mRNA delivery efficacy. 306Oi10 can be used in research related to mRNA delivery .

HY-147079

Egaptivon pegol ARC 1779		Aptamers
Egaptivon pegol (ARC1779) is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol has anti-thrombotic efficacy.

HY-138912

Cho-Arg TFA		Cholesterol
Cho-Arg TFA is a steroid-based cationic lipid with an L-Arginine headgroup. Cho-Arg TFA shows a remarkably high optimized plasmid DNA transfection efficacy .

HY-W352344

2'-Deoxy-L-adenosine		Nucleosides and their Analogs
2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

efficacy

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Natural
Products